Post-marketing Surveillance to Assess the Safety of Boostrix Vaccine Given According to Prescribing Information in Korea


The purpose of this study is to collect safety information from pre-adolescents, adolescents and adults after Boostrix vaccination is administered according to the approved prescribing information in Korea.

Full Title of Study: “Assessment of Safety of GlaxoSmithKline (GSK) Biologicals’ Combined Reduced Antigen Content Diphtheria-tetanus Toxoids and Acellular Pertussis Vaccine (dTPa), Boostrix When Administered According to the Approved Prescribing Information in Korea”

Study Type

  • Study Type: Observational
  • Study Design
    • Time Perspective: Prospective
  • Study Primary Completion Date: January 11, 2016

Detailed Description

Protocol amendment 3 rationale was as follows: – Age for analysis set is specified. – Subjects with pregnancy will be analyzed by their pregnancy status before/after vaccination. – Pregnancy notifications must be done within 2 weeks


  • Biological: Boostrix
    • Single intramuscular injection
  • Other: Safety data collection
    • Safety monitoring: recording of adverse events using diary cards and recording of serious adverse events using the latest version of Korea’s Post-Marketing Surveillance Serious Adverse Event Reporting Form

Arms, Groups and Cohorts

  • Boostrix Group
    • Pre-adolescents (aged (≥10 years to ˂12 years), adolescents (aged ≥12 to ˂19 years), adults (aged 19 to 64 years) and elderly (≥ 65) who received Boostrix as a part of routine practice at a private clinic or hospital in Korea.

Clinical Trial Outcome Measures

Primary Measures

  • Number of Unexpected Adverse Events (AEs)
    • Time Frame: During the 30-day (Day 0 – Day 29) follow-up period after vaccination.
    • Unexpected AEs were defined as adverse events that are not reflected in the approved Prescribing Information in Korea.
  • Number of Expected AEs.
    • Time Frame: During the 30-day (Day 0 – Day 29) follow-up period after vaccination.
    • Expected AEs were defined as an adverse event that was expected from the subject during the post-vaccination follow-up period as described in the locally approved Prescribing Information in Korea.
  • Number of Subjects With Serious Adverse Events (SAEs)
    • Time Frame: During the 30-day (Day 0 – Day 29) follow-up period after vaccination.
    • An SAE was defined as any AE that resulted in death, was life-threatening, required hospitalization or prolongation of hospitalization, resulted in disability/incapacity or that was a congenital anomaly/birth defect in the offspring of a study subject.

Participating in This Clinical Trial

Inclusion Criteria

  • Written or signed informed consent obtained from the subject/ subject's parent(s)/Legally Acceptable Representative(s) of the child. Korean male or female subjects who were recently vaccinated or eligible to receive Boostrix according to the locally approved Prescribing Information. Exclusion Criteria:

  • Those who are not eligible for vaccination according to the local Prescribing Information. – Child in care.

Gender Eligibility: All

Minimum Age: 10 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: Accepts Healthy Volunteers

Investigator Details

  • Lead Sponsor
    • GlaxoSmithKline
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • GSK Clinical Trials, Study Director, GlaxoSmithKline


Park HJ, Kim SJ, Song R, Chen J, Kim JH, Devadiga R, Kang HC. A 6-year Prospective, Observational, Multi-Center Post-Marketing Surveillance of the Safety of Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis (Tdap) Vaccine in Korea. J Korean Med Sci. 2019 Mar 22;34(12):e105. doi: 10.3346/jkms.2019.34.e105. eCollection 2019 Apr 1.

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.